{"entity":{"id":"fhp-health-center-guam","kind":"institution","name":"FHP Health Center, Guam","aka":["FHP Health Center-Guam","TakeCare Asia FHP Health Center"],"tldr":"A health centre in Tamuning, Guam, that since 2019 has let patients on Guam join United States National Cancer Institute trials locally.","summary":"The University of Guam reported in 2019 that the National Cancer Institute had approved, in January, the addition of FHP Health Center, Guam, to its Community Oncology Research Program (NCORP) through the University of Hawai'i Cancer Center's Minority/Underserved NCORP, allowing patients in Guam to take part in NCI-sponsored cancer clinical trials, which the Cancer Research Center of Guam would facilitate. The site's principal investigator, Dr Samir Ambrale, said 95 per cent of cancer care is delivered locally in Guam. ClinicalTrials.gov lists \"FHP Health Center-Guam\" in Tamuning as a site for NCI-MATCH, ALCHEMIST, DART (S1609) and other cooperative group trials. OnCo could not reach FHP's own site. The coordinates are an approximate Tamuning city point.","asOf":"2026-11-11","links":[{"label":"University of Guam: Cancer Research Center to facilitate clinical trials for Guam cancer patients (2019)","url":"https://uog.edu/news-announcements/2018-2019/2019-cancer-research-center-to-facilitate-clinical-trials-for-guam-cancer-patients.php"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["guam-cancer-registry"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tamuning","country":"GU","lat":13.497,"lng":144.777,"institutionType":"hospital","programs":["NCI Community Oncology Research Program site (since 2019)","Cancer clinical trials"]},"route":"/institutions/fhp-health-center-guam/","neighbours":{"institution":[{"id":"guam-cancer-registry","kind":"institution","name":"Guam Cancer Registry","route":"/institutions/guam-cancer-registry/"}],"trial":[{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/"},{"id":"dart-s1609","kind":"trial","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","route":"/trials/dart-s1609/"},{"id":"nct04137107","kind":"trial","name":"Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer","route":"/trials/nct04137107/"},{"id":"nct07018869","kind":"trial","name":"Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors","route":"/trials/nct07018869/"},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/"},{"id":"nct04267848","kind":"trial","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","route":"/trials/nct04267848/"},{"id":"nct04092283","kind":"trial","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","route":"/trials/nct04092283/"},{"id":"nct03793179","kind":"trial","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","route":"/trials/nct03793179/"}]}}